Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Products Facilitate Sample Enrichment for Next-Generation Sequencing Protocols

By LabMedica International staff writers
Posted on 16 Oct 2012
A new line of products that enables the enrichment of the whole exome (the part of the genome formed by exons, the coding portions of genes that are expressed) or custom regions of interest is now available for biotech researchers using next-generation technology DNA sequencing protocols.


The new Roche NimbleGen (Madison, WI, USA) "SeqCap EZ Exome Plus Library" enables researchers to create their own target enrichment discovery tools by adding up to 50 Mb of custom targets to the existing 64 Mb EZ Exome v3 products providing the ability to target and enrich up to 114 Mb of total genomic DNA.

NimbelGen’s SeqCap EZ Library is a liquid-based enrichment technology, which enables the targeted capture for subsequent sequencing of the exome or a targeted subset of genes. More...
SeqCap EZ Library is compatible with various sequencing chemistries and with the addition of the Caliper Sciclone NGS Workstation, provides a comprehensive high-throughput target enrichment solution. Caliper Life Sciences (Hopkinton, MA, USA) is a leading provider of innovative liquid handling and microfluidic systems and has broad expertise in automating the processes involved in these core areas of genomics research including: extraction and purification, PCR reaction setup, automation of RT (real time)-PCR as well as the separation and direct detection of DNA and RNA.

In addition to the SeqCap EZ Library Roche NimbleGen has released new disease-specific target enrichment panels for clinical research applications. These include the SeqCap EZ Comprehensive Cancer Design, which covers 578 genes implicated in a wide range of common and rare cancers, and the SeqCap EZ Neurology Panel Design, which covers 256 genes associated with 87 neurological disorders, including Parkinson’s disease, Alzheimer’s disease, epilepsy, and autism.


“We are extremely excited to expand our targeted sequencing portfolio to meet the rapidly evolving needs of researchers in the field of next-generation sequencing,” said Thomas Schinecker, head of sequencing solutions at Roche NimbleGen. “Our proven industry leading performance in target enrichment technology gives us a strong foundation to offer these new solutions to researchers in basic research and translational research laboratories. In addition, we are looking forward into early next year when we will be launching new SeqCap EZ Reagents to provide customers with additional workflow convenience.”

Related Links:
Roche NimbleGen
Caliper Life Sciences



Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sample Transportation System
Tempus1800 Necto
Gold Member
Collection and Transport System
PurSafe Plus®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.